Neil Shah

22PUBLICATIONS
180CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 17, 2026
Rule-Based Identification of a Reliable Real-World Cancer Recurrence Endpoint.

|Jul 25, 2026
Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients.

|May 05, 2026
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

|Nov 02, 2025
Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes.

Heather Derry-Vick, Neil J Shah, Jaeil Ahn

|Oct 13, 2025
Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Neil J Shah, Reshma Shinde, Rituparna Bhattacharya

|Jun 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.

Kathryn E Beckermann, Neil J Shah, Matthew T Campbell

Pageof 4

Frequent Collaborators

4 joint publications

Robert J Motzer

4 joint publications

Maria Isabel Carlo

4 joint publications

Ritesh R Kotecha

3 joint publications

Michael B Atkins